You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

5274 Results
Document
New
Jan 2025
Document
New
Jan 2025
Guidelines and Advice
Status: Current
Version: 2
Dec 2024
Drug
Other Name(s): Lynparza®
Quick Link(s): Drug Monograph, Patient Info Sheet
Jan 2025
Document
New
Jan 2025
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    fulvestrant
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
capivasertib (Unfunded),
fulvestrant
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jan 2025
The Ontario Steering Committee for Cancer Drugs (OSCCD) was created in 2013 to enhance and support the administration of Ontario's cancer drug...
Le Comité directeur de l’Ontario pour les médicaments contre le cancer (CDOMC) a été constitué en 2013 pour élargir et soutenir l’administration des...
Drug
Other Name(s): Padcev®
Quick Link(s): Drug Monograph, Patient Info Sheet
Jan 2025
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Enfortumab Vedotin - Previously Treated Advanced or Metastatic Urothelial Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
enfortumab vedotin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jan 2025
Senior Scientist, Indigenous Cancer Care Unit, Acute and Hospital-Based Care, Ontario Health Lead Scientist amanda.sheppard@ontariohealth.ca

Pages